Having problems with message search?
SAVE ADAP PHONE ZAP –
CALL ROCHE PHARMACEUTICALS AND DEMAND LIFESAVING ACCESS TO FUZEON NOW!
Did you know there are nearly 100 people who need Fuzeon and can’t get it because their AIDS Drug Assistance Programs (ADAP) can’t afford to cover the drug?
Roche, the maker of Fuzeon, is playing hard ball by refusing to lower the price of Fuzeon for ADAPs, and denying people the drug through their patient assistance program.
According to the Roche Patient Assistance Foundation Website:
"We are committed to making sure every patient who needs our drug gets it."
Call Fred Schmid, Roche’s Vice President of Antiretrovirals at 973-562-3171 and tell him:
"Don’t be a scrooge, Stop using PWAs’ lives as bargaining chips, honor your pledge to the AIDS community and lift the ADAP restriction on Fuzeon Patient Assistance now!"
Background:
What is Fuzeon?
Fuzeon is the only entry inhibitor approved by the FDA for the treatment of HIV infection. Research has shown that this drug can help some people suppressed HIV when other drugs no longer work, especially if it is combined with another new agent. It has given many long-term survivors another fighting chance. Fuzeon is also the most expensive HIV drug ever marketed, costing nearly $28,000 per year, twice the cost of a standard three-drug combination.
Why can’t people get the drug?
Hundreds of people are on waiting lists for the AIDS Drug Assistance Programs (ADAP) across the country due to severe funding shortages. Despite this fact, Roche is only offering a minimal discount, not enough to allow full Fuzeon coverage in 21 ADAPs. Playing hard ball, Roche made the unprecedented decision to use their Patient Assistance Program restriction as a negotiation tactic, denying Fuzeon to ADAP clients living in states without full coverage of the drug. Since ADAPs are the publicly funded providers of last resort, this restriction amounts to a death sentence for people running out of other treatment options.
Where do these people live?
Nine ADAPs do not cover Fuzeon at all – Hawaii, Idaho, Kentucky, Nebraska, New Hampshire, North Dakota, South Dakota, West Virginia, Wyoming
Twelve ADAPs have caps on the number of people who can get Fuzeon – Alabama (reached the cap of 12- with 7 additional people waiting), Arkansas (5), District of Columbia (25), Florida (100), Georgia (6),
Louisiana (reached the cap of 20 – with 2 additional people waiting), Minnesota (25), New Mexico (5), Ohio (30), Texas (reached the cap of 50 – with 82 additional people waiting), Vermont (4), Washington (25)
The Save ADAP Committee is a Working Group of the AIDS Treatment Activists Coalition (ATAC), a national coalition of AIDS treatment activists and policy advocates. Working in conjunction with ADAP clients and service providers on the grassroots level, Save ADAP aims to ensure adequate funding for the AIDS Drug Assistance Program. If you would like to be part of SAVE ADAP, please send an email to Robert Reed at robert4policy@...
CALL ROCHE PHARMACEUTICALS AND DEMAND LIFESAVING ACCESS TO FUZEON NOW!
Did you know there are nearly 100 people who need Fuzeon and can’t get it because their AIDS Drug Assistance Programs (ADAP) can’t afford to cover the drug?
Roche, the maker of Fuzeon, is playing hard ball by refusing to lower the price of Fuzeon for ADAPs, and denying people the drug through their patient assistance program.
According to the Roche Patient Assistance Foundation Website:
"We are committed to making sure every patient who needs our drug gets it."
Call Fred Schmid, Roche’s Vice President of Antiretrovirals at 973-562-3171 and tell him:
"Don’t be a scrooge, Stop using PWAs’ lives as bargaining chips, honor your pledge to the AIDS community and lift the ADAP restriction on Fuzeon Patient Assistance now!"
Background:
What is Fuzeon?
Fuzeon is the only entry inhibitor approved by the FDA for the treatment of HIV infection. Research has shown that this drug can help some people suppressed HIV when other drugs no longer work, especially if it is combined with another new agent. It has given many long-term survivors another fighting chance. Fuzeon is also the most expensive HIV drug ever marketed, costing nearly $28,000 per year, twice the cost of a standard three-drug combination.
Why can’t people get the drug?
Hundreds of people are on waiting lists for the AIDS Drug Assistance Programs (ADAP) across the country due to severe funding shortages. Despite this fact, Roche is only offering a minimal discount, not enough to allow full Fuzeon coverage in 21 ADAPs. Playing hard ball, Roche made the unprecedented decision to use their Patient Assistance Program restriction as a negotiation tactic, denying Fuzeon to ADAP clients living in states without full coverage of the drug. Since ADAPs are the publicly funded providers of last resort, this restriction amounts to a death sentence for people running out of other treatment options.
Where do these people live?
Nine ADAPs do not cover Fuzeon at all – Hawaii, Idaho, Kentucky, Nebraska, New Hampshire, North Dakota, South Dakota, West Virginia, Wyoming
Twelve ADAPs have caps on the number of people who can get Fuzeon – Alabama (reached the cap of 12- with 7 additional people waiting), Arkansas (5), District of Columbia (25), Florida (100), Georgia (6),
Louisiana (reached the cap of 20 – with 2 additional people waiting), Minnesota (25), New Mexico (5), Ohio (30), Texas (reached the cap of 50 – with 82 additional people waiting), Vermont (4), Washington (25)
The Save ADAP Committee is a Working Group of the AIDS Treatment Activists Coalition (ATAC), a national coalition of AIDS treatment activists and policy advocates. Working in conjunction with ADAP clients and service providers on the grassroots level, Save ADAP aims to ensure adequate funding for the AIDS Drug Assistance Program. If you would like to be part of SAVE ADAP, please send an email to Robert Reed at robert4policy@...
Offline 
Send Email